Our executives (CEO, VPs, and statutory directors) are granted shares issued by Dexco provided they meet their performance targets. This payment is released based on Dexco’s five-year strategic plan.

The performance target is set annually by our People, Governance, and Appointments Committee and approved by our Managing Board. Share transfers are subject to a five-year grace period and the participant’s continuity at Dexco.

The number of shares will be calculated using the average trading price as a baseline. In case of dismissal without cause or no job reinstatement, from the 37th month onwards, the participant will receive, after a five-year period, an amount of shares that corresponds to time worked. However, if the participant quits Dexco, they will lose their stock options, regardless of time elapsed.

We invite the beneficiary to purchase the company’s shares, investing a percentage of their net Short-Term Incentive earnings. Share matching will occur as follows:

• Four years after the initial investment, Dexco transfers 50% of the shares to the beneficiary, who may sell only the transferred shares;
• The full 100% matching occurs when the investment is kept for five years. After that, 50% of the remaining shares are transferred to the beneficiary. However, in case they sell the shares before the end of the grace period, the beneficiary loses the right to matching;
• The transfer is also conditioned to the beneficiary’s continuity at Dexco. If they are dismissed without cause or don’t have their job reinstated, from the 13th month on, they will be entitled to matching pro rata temporis, to be paid off by the end of the five-year period. The matching plan will apply only to non-employee directors (statutory directors).